AADI Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 16:00):

Stats
Today's Volume	136 903
Average Volume	351 373
Market Cap	45.18M
EPS	$0 ( 2024-03-13 )
Next earnings date	( $-0.660 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.750
ATR14	$0.00400 (0.22%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Desai Neil	Sell	17 772	Common Stock
2024-04-02	Desai Neil	Sell	22 228	Common Stock
2024-03-01	Desai Neil	Sell	27 036	Common Stock
2024-03-04	Desai Neil	Sell	14 964	Common Stock
2024-03-01	Itri Lorettta M	Buy	76 813	Stock option (right to buy)

INSIDER POWER
65.15
Last 91 transactions
Buy: 5 312 775 \| Sell: 803 060

Volume Correlation

Long: 0.05 (neutral)

Short: 0.00 (neutral)

Signal:(70.613) Neutral

Aadi Bioscience, Inc. Correlation

10 Most Positive Correlations
NAKD	0.963
AVIR	0.957
CCSI	0.954
SMSI	0.95
CSGP	0.94
GAMB	0.937
ASYS	0.937
REFI	0.936
NVCT	0.935
TTCF	0.933

10 Most Negative Correlations
MBIN	-0.967
SLMBP	-0.966
PRAA	-0.956
ZIONP	-0.955
VRCA	-0.954
MDXG	-0.953
TIGO	-0.953
PCYG	-0.949
IDCC	-0.949
ADMS	-0.947

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Aadi Bioscience, Inc. Correlation - Currency/Commodity

-0.06
( neutral )

-0.12
( neutral )

0.00
( neutral )

0.22
( neutral )

Aadi Bioscience, Inc. Financials

Annual	2023
Revenue:	$24.35M
Gross Profit:	$21.55M (88.47 %)
EPS:	$-2.44

Q4	2023
Revenue:	$6.33M
Gross Profit:	$5.40M (85.35 %)
EPS:	$-0.600

Q3	2023
Revenue:	$5.96M
Gross Profit:	$5.26M (88.30 %)
EPS:	$-0.600

Q2	2023
Revenue:	$6.20M
Gross Profit:	$5.55M (89.42 %)
EPS:	$-0.670

Financial Reports:

No articles found.

Aadi Bioscience, Inc.

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.